Abstract 2701
Background
The basic scope of population-based cancer registries (CRs) is to collect data that enable computation of cancer incidence. In addition to this, nowadays most registries can provide more extensive information such as data on stage and treatment, which could be used to assess and compare different care pathways. The current analysis reports on treatment by stage patterns for female breast cancer in Europe.
Methods
Data from CRs included in the European Cancer Information System (ECIS) and having submitted data on stage and treatment for the ENCR-JRC project were analysed. Proportion of cases by treatment type: surgery (SG), radiotherapy (RT), systemic therapy (ST), by stage, age, period and region were calculated.
Results
829,247 cases from 20 CRs were analysed. Treatment for stage I (UICC TNM) patients aged 19-74 in 1999-2005 was SG alone (22%), SG+ST (13%) SG+RT (31%), SG+RT+ST (32%). SG alone decreased to 18%, while SG+RT+ST rose to 37% in 2006-13. High variability was observed: in Eastern Europe SG alone was 31%, SG+ST 17%, SG+RT 24%, SG+RT+ST 23% in 2006-13, in Western Europe SG alone was 12%, SG+ST 13%, SG+RT 31%, SG+RT+ST 43%. For age 75+ in 1999-2005 SG (37%) and SG+ST (20%) were higher than in 19-74 patients, while SG+RT (17%) and SG+RT+SG (15%) were lower. SG decreased to 31%, SG+RT+ST rose to 20% in 2006-13. Untreated patients were 3% in both periods. For the regional comparison, in 2006-13 SG alone was 50% in Eastern Europe vs 25% in Western Europe; SG+RT+ST was 9% in Eastern Europe, 24% in Western Europe. In 2006-13 for younger stage IV patients SG alone was 7%, ST alone 29%, SG+ST 18%, SG+RT+ST 14%, no treatment 9%. For 75+ patients SG was 11%, ST 30%, SG+ST 12%, SG+RT+ST 7%, no treatment 15%.
Conclusions
Variability in treatment patterns was observed by stage, age, period and region. Clinical information from CRs should be routinely used to monitor clinical care patterns, according to national and international recommendations, to compare levels of compliance and inform policy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
European Commission.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4842 - The analysis of genomic signatures of head and body/tail of pancreatic cancer in Chinese patients
Presenter: Qi Ling
Session: Poster Display session 2
Resources:
Abstract
4988 - MGMT methylation in metastatic pancreatic cancer (mPAC): a single center experience
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5035 - Advantage of three-dimensional image analysis of pancreatic cancer using computed tomography
Presenter: Seung Bae Yoon
Session: Poster Display session 2
Resources:
Abstract
1465 - Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer.
Presenter: Susumu Hijioka
Session: Poster Display session 2
Resources:
Abstract
1982 - Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trial
Presenter: Mairead McNamara
Session: Poster Display session 2
Resources:
Abstract
2244 - FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: a propensity score analysis
Presenter: Angélique Vienot
Session: Poster Display session 2
Resources:
Abstract
4557 - Cellfree tumor-DNA (cfDNA) as a very early predictor of therapeutic outcome in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Sabine Payr
Session: Poster Display session 2
Resources:
Abstract
4406 - Comprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations
Presenter: Milind Javle
Session: Poster Display session 2
Resources:
Abstract
4283 - Phase II Monotherapy Efficacy of Cancer Metabolism Targeting SM-88 in Heavily Pre-Treated PDAC Patients.
Presenter: Allyson Ocean
Session: Poster Display session 2
Resources:
Abstract
2078 - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial
Presenter: Antoine Hollebecque
Session: Poster Display session 2
Resources:
Abstract